Global Artificial Pancreas Devices System Market 2016-2020
About Artificial Pancreas Devices System
Artificial organs are human-made bioartificial devices, which are implanted or integrated into individuals to replace or support natural organs. These include artificial heart, kidney, pancreas, and cochlear implants. Biocompatible materials such as polymers (polyurethane, polysulfone, and porous polypropylene), biologics, ceramics, and metals are used to develop artificial organs. These organs are incorporated with different technologies like sensors, biomaterials, and innovative delivery systems. Artificial organs perform the function of the natural organ and help the patient to live a quality life. In few cases, artificial organs are capable of eliminating the need for organ transplantation altogether.
Technavio’s analysts forecast the global artificial pancreas devices system market to grow at a CAGR of 7.40% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global artificial pancreas devices system market for 2016-2020. To calculate the market size, the report considers the revenue generated from sales of the different products.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Artificial Pancreas Devices System Market 2016-2020
Technavio recognizes the following companies as the key players in the global artificial pancreas devices system market: Medtronic, Johnson & Johnson, Insulet, Tandem Diabetes Care, and Roche.
Other Prominent Vendors in the market are: Beta Bionics, Bigfoot Biomedical, Cellnovo, Dexcom, Dose Safety, DreaMed Diabetes, Inreda Diabetic, and Type Zero Technologies.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is increasing focus on closed loop systems. The increasing demand for APDS has driven the vendors to undertake extensive clinical trials toward product improvement, which are expected to have a positive impact on the market growth. The vendors such as Medtronic, Tandem Diabetes Care, Johnson & Johnson, and Insulet are currently focusing on the development of closed loop APDS, which is expected to propel the market growth owing to its potential advantages compared with existing APDS. The existing open loop APDS are low glucose suspend devices with semi-automation. As these systems are not integrated with advanced algorithms, the required user intervention is at a moderate level. On the contrary, closed-loop APDS are externally worn medical devices, which would enable individuals with type 1 diabetes to regulate blood glucose levels in a fully automated way with zero intervention required from the user.”
According to the report, one driver in the market is increasing initiatives of research organizations fostering innovation in the market. The inspiring initiatives of research organizations such as JDRF enable the development of innovative products in the market. JDRF launched Artificial Pancreas Project in 2006 to foster the development of an artificial pancreas to help individuals with diabetes. Subsequently, JDRF collaborated with Medtronic in 2014 to develop a novel redundant sensor system, which is designed to boost the accuracy and reliability of APDS. The research also focused on the development of orthogonally redundant sensor system, which integrates an electrochemical sensor along with an optical sensor to provide accurate glucose values. Earlier, in June 2013, JDRF collaborated with BD for a three-year time period to develop a single optimized device that will handle multiple functions and avoid the need and complexities of dwelling catheters. Recently, the researchers at Harvard University started a program to identify and develop an effective treatment for type 1 diabetes. Subsequently, National Institutes of Health awarded $12.5 million to Harvard University in 2016 to undertake the field testing of two artificial pancreas algorithms. Such initiatives lead to the development of novel products as well as upgradation of existing systems.
Further, the report states that one challenge in the market is lack of smart control algorithms affecting the adoption rate of existing APDS. Though there are important developments in sensor and pump technology, the APDS is associated with the delays and inaccuracies in glucose sensing and insulin delivery. Such type of issues occurs when there is a disturbance in the routine system (such as uptake of meal), which triggers a rapid glucose rise that is significantly faster than the time required for insulin absorption and action. Thus, the vendors should focus on designing an APDS with smart sensors that consider a relatively slow response, giving time for the delays to fade before the next control action. In particular, to avoid hypoglycemia after a meal, the vendors has to design a moderately aggressive controller. This has driven the vendors to research on new control design, model predictive control (MPC) algorithm, which is based on a prediction of glucose dynamics using a model of the individual's metabolic system. According to clinical studies, this design may be better for mitigation of time delays due to subcutaneous glucose sensing and insulin infusion. However, such smart algorithms have limited clinical evidence, and it may take few more years to develop an ideal algorithm.
Medtronic, Johnson & Johnson, Insulet, Tandem Diabetes Care, Roche, Beta Bionics, Bigfoot Biomedical, Cellnovo, Dexcom, Dose Safety, DreaMed Diabetes, Inreda Diabetic, Type Zero Technologies.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook